YD Diagnostics Co., Ltd. – Trademark Portfolio

Entity Type: 99

YD Diagnostics Co., Ltd. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include YD and URISCAN.

76, Seori-ro, Idong-eup,

Cheoin-gu, Yongin-si Gyeonggi-do

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

YD
YD
Registered 2025
URISCAN
URISCAN
Registered 2023

Trademark Classifications

YD Diagnostics Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (3 filings)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does YD Diagnostics Co., Ltd. have?

YD Diagnostics Co., Ltd. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does YD Diagnostics Co., Ltd. file in?

YD Diagnostics Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are YD Diagnostics Co., Ltd.'s most well-known trademarks?

YD Diagnostics Co., Ltd.'s registered trademark portfolio includes well-known marks such as YD and URISCAN. These are among 2 currently registered trademarks in the portfolio.

What is YD Diagnostics Co., Ltd.'s trademark registration success rate?

YD Diagnostics Co., Ltd. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.